Waters Corp appoints Dan Brennan and Mark Vergnano to Board of Directors

WATERS CORP /DE/

Board expanded from 7 to 9 members; appointments effective November 23, 2022.
Brennan is EVP & CFO of Boston Scientific; Vergnano is former Chairman, President & CEO of Chemours.
Each receives initial equity grant valued at $36,666 (50% RSU, 50% NSO) vesting in one year, plus prorated cash retainer of $7,418.
Both deemed independent under NYSE standards; board now 8 of 9 independent, 5 appointed in last 5 years.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mark P. Vergnano

Director

WAT · WATERS CORP /DE/

Effective: 2022-11-23
Filed: November 23, 2022, 6:59 PM ET

appointed Dan Brennan and Mark P. Vergnano to the Board, effective November 23, 2022

Appointed

Dan Brennan

Director

WAT · WATERS CORP /DE/

Effective: 2022-11-23
Filed: November 23, 2022, 6:59 PM ET

appointed Dan Brennan and Mark P. Vergnano to the Board, effective November 23, 2022

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark P. Vergnano was appointed as Director at WATERS CORP /DE/.

Action: appointed
Role: Director

Exact text from the filing

appointed Dan Brennan and Mark P. Vergnano to the Board, effective November 23, 2022

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Dan Brennan was appointed as Director at WATERS CORP /DE/.

Action: appointed
Role: Director

Exact text from the filing

appointed Dan Brennan and Mark P. Vergnano to the Board, effective November 23, 2022

View on SEC.gov

WATERS CORP /DE/ filing history →

Source: SEC EDGAR

accession 0001193125-22-291639

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.